VIVUS is part of the healthcare sector and biotechnology industry. The company CEO is John Amos. VIVUS Incis a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. Its product line includes Qsymia for sleep apnea, STENDRA for erectile dysfunction.



Previous Intraday Performance:

The VVUS shares had a previous change of 2.39% which opened at 3.93 and closed at 3.90. It moved to an intraday high of 3.99 and a low of 3.83.

SeekingAlpha:  VIVUS, Inc. (VVUS) CEO John Amos on Q1 2019 Results – Earnings Call Transcript

Historical Performance:

Over the last five trading days, VVUS shares returned -0.26% and in the past 30 trading days it returned 16.77%. Over three months, it changed -22.00%. In one year it has changed -58.27% and within that year its 52 week high was 9.88 and its 52 week low was 2.15. VVUS stock is 81.40% above its 52 week low.

Our calculations result in a 200 day moving average of 4.27 and a 50 day moving average of 3.92. Right now, VVUS stock is trading -8.73% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Vivus beats by $0.42

Liquidity:

The company has a market cap of $42.5m with 10.6m shares outstanding and a float of 8.2m shares. Trading volume was 6,312 shares and has experienced an average volume of 62,234 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for VIVUS was -3.49 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -1.17.

1stQtr 2019 -0.754thQtr 2018 -0.423rdQtr 2018 -0.872ndQtr 2018 -1.201stQtr 2018 -1.00

The growth of the EPS is critical in understanding the current valuation of VIVUS; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 37.40% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 21.60% of institutional ownership.

The beta was calculated to be 2.00.



SeekingAlpha:  Vivus beats by $0.42

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -13.24%, profit margin is -49.81%, price-to-sales is 0.61 and price-to-book is 127.20.

Company Score Card:

Results are out of six:
 1  : Growth Expectations Result
 1  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 0  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here